Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerAlpelisib plus Olaparib for Triple-Negative Breast Cancer

@CRC_AACR @dralexswarbrick @uni_tue https://t.co/lETglcJGR7

RT @nursekristinrn: Research indicates that long time use of alpelisib may eventually cause changes genomically which may be targeted with…

RT @nursekristinrn: Research indicates that long time use of alpelisib may eventually cause changes genomically which may be targeted with…

Research indicates that long time use of alpelisib may eventually cause changes genomically which may be targeted with PARP inhibitor such as Olaparib. This study in TNBC is promising. I feel a sense of urgency to encourage focus on more types of Breast Ca